Every year, the doctors we rely on are required to complete continuing medical education to stay current. It's a real requirement — tracked, audited, and tied to keeping a license active. But there's a question underneath that requirement that doesn't get asked nearly often enough: who pays for it?
The common wisdom has been that Big Pharma funds roughly 30% of it. It turns out that was only part of the story. According to the ACCME's 2024 Annual Data Report, the fuller picture looks like this:
Taken together, more than 40% of continuing medical education funding — roughly $1.5 billion altogether — comes from pharmaceutical and medical-device companies.
That's not a small stakeholder quietly underwriting a conference coffee bar. That's close to half the system.
What I Saw From the Inside
I can tell you this isn't abstract, because I lived it. I worked as an infusion nurse in oncology, and just like the doctors, we were required to complete continuing education every year to keep our licenses. The drug companies sent their most attractive, most polished representatives to put on elaborate CEU parties, complete with gifts, perks, and trips. This was the early nineties. Things eventually tightened up, but I was there before they did, and I saw it happen firsthand.
The “patient support” products told their own story: pink neck pillows, pink ribbon T-shirts, pink nausea bands — all branded, all free, all courtesy of the same companies whose drugs we were infusing. And then there were the truly impressive tools: prescription pads with the chemotherapy agent already printed on them, and calculators built specifically to handle the hard math — weight, kidney function, liver function — so that all a doctor had to do was fill in one number, and presto, out came a conveniently calculated dose.
That was playing out alongside the pain medications, too — the OxyContin years, happening in our office every single day. And every year, we dutifully earned our continuing education credits to keep our licenses current, education built almost entirely on Big Pharma's own research. Mindblowing to think about, now that I've woken up to it.
What That Money Actually Touches
It's worth being precise about what these dollars fund, because not all industry money touches the same part of the machine. Direct grants tend to fund the content itself — the courses, the modules, the topics chosen for a given year's curriculum. Advertising and exhibit fees fund something a step removed — booth space, conference sponsorships, the visible presence of a company's name in the room. Both are industry money flowing into the same institutions that train and re-license physicians. But if you're trying to understand influence specifically over what doctors are taught, the direct grants are the sharper edge of that question, and the advertising dollars are the broader atmosphere around it.
Either way, when nearly half of a profession's ongoing education budget comes from the companies whose products that profession will go on to prescribe, it's fair — not cynical — to ask how that shapes things. What subjects get chosen. Which speakers get elevated to teach them. Which treatments get emphasized, and which get quietly left off the syllabus.
Could that help explain why oncologists rarely hear much about the potential of already-approved, repurposed medicines being studied for cancer — drugs that are cheap and off-patent, and therefore nobody's marketing budget? Or why psychiatrists so often reach for the prescription pad before a fuller conversation about alternatives has even happened? Those are open questions, not proven conclusions, but they're the right questions to be asking once you see where the funding actually comes from.
How We Got Here
Continuing medical education wasn't always built this way. For most of its history, it was largely a profession teaching itself — run by medical societies, universities, and hospitals, with a simple stated purpose: keep physicians current, and improve patient care.
That started to shift by the mid-2000s, when industry money had grown to supply roughly half of all CME funding. It got enough attention that the U.S. Senate opened an investigation, and found that drug companies were using educational grants for something beyond education — they were using them to build markets and shape what doctors were being taught in the process.
Reforms followed. Disclosure requirements tightened. Firewalls between funders and course content were supposed to go up. And yet, twenty years later, the number sitting in front of us is still north of 40 cents on every dollar.
The Question Worth Sitting With
None of this means every course funded this way is compromised, or that every physician who attends one is being quietly steered. Most doctors go into medicine to help people, and plenty of legitimate, rigorous education gets funded by industry dollars alongside everything else.
But a system that depends this heavily on the companies it's supposed to be training people to evaluate objectively isn't a neutral system — it's a system with a thumb on the scale, whether or not any single person in the room means it that way. The honest response isn't outrage, it's attention. Know where your doctor's information comes from. Ask questions when a treatment gets recommended quickly and without much discussion of alternatives. The system doesn't need to be perfect for that kind of awareness to matter — it just needs you to be paying attention.
As Socrates put it, I know that I know nothing. But I will do my best to give you the truth.